Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-TAB in Multiple Sclerosis
NCT02442570Phase 2Completed
- Start
- Sep 2012
- Primary completion
- Jun 2014
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SER-101 in multiple sclerosis (MS) (4 arms). Primary endpoint: Safety (adverse events) at 48 weeks. Started Sep 2012; status: completed.
02
Drugs
SER-101
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02442570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442570.